StockNews.com Begins Coverage on Sorrento Therapeutics (NASDAQ:SRNE)

StockNews.com assumed coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a report released on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Up 3.7 %

Shares of SRNE opened at $0.01 on Tuesday. The stock’s 50-day moving average price is $0.02 and its two-hundred day moving average price is $0.04. Sorrento Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.42.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.